ArticleClinical rheumatology2006
Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis--a population-based survey.
Article in Clinical rheumatology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 4 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Brazilian recommendations for the use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis.Advances in rheumatology (London, England) · 2021Guideline
- [Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations].Zeitschrift fur Rheumatologie · 2019Guideline
- Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials.Annals of the rheumatic diseases · 2016Pooled it
- [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures].Zeitschrift fur Rheumatologie · 2014Guideline
- Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis.Arthritis research & therapy · 2019Trial
- Analysis of relapse rates and risk factors of tapering or stopping pharmacologic therapies in axial spondyloarthritis patients with sustained remission.Clinical rheumatology · 2018Trial
- Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials.Annals of the rheumatic diseases · 2014Trial
- Evaluation of the short-term efficacy of NSAIDs on patients with active ankylosing spondylitis in daily practice: a 3-month, longitudinal, observational study.Rheumatology international · 2010Trial
- Difficult-to-treat axial spondyloarthritis patients.Archives of rheumatology · 2024Article
- Current Pharmacological Therapies for the Management of Spondyloarthritis: Special Considerations in Older Patients.Drugs & aging · 2023Review
- [Development of quality standards for patients with axial spondyloarthritis for use in Germany].Zeitschrift fur Rheumatologie · 2022Article
- Upregulated lncRNA-NEF predicts recurrence and poor treatment outcomes of ankylosing spondylitis.Immunity, inflammation and disease · 2022Article
- Treatment of axial spondyloarthritis: an update.Nature reviews. Rheumatology · 2022Review
- [Spondyloarthritides].Zeitschrift fur Rheumatologie · 2017Review
- Have the annual trends of total knee arthroplasty in ankylosing spondylitis patients decreased?Annals of translational medicine · 2017Article
- [Spondyloarthritides].Der Internist · 2017Review
- Efficacy and safety of celecoxib in chinese patients with ankylosing spondylitis: a 6-week randomized, double-blinded study with 6-week open-label extension treatment.Current therapeutic research, clinical and experimental · 2014Article
- Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis.Best practice & research. Clinical rheumatology · 2014Review
- [Spondyloarthritides].Der Internist · 2011Article
- A Review of Topical Diclofenac Use in Musculoskeletal Disease.Pharmaceuticals (Basel, Switzerland) · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of the study is to describe the use, clinical efficacy, and toxicity of nonsteroidal anti-inflammatory drug (NSAID) therapy in patients with ankylosing spondylitis (AS). A cross-sectional population study of 1,080 AS patients was carried out by a written questionnaire in the year 2000. Seventy-eight percent of AS patients had regularly taken NSAIDs for their disease 12 months prior to the study. Most AS patients commonly used diclofenac, naproxen and indomethacin. AS patients were generally rather satisfied with the efficacy of their therapy where 19.1% reported complete pain control, 26.8% reported pain reduction to one quarter, and a further 34.4% reported pain reduction to one half. However, over 20% of patients taking NSAIDs still reported insufficient pain control and more than 40% changed the NSAID due to lack of efficacy. One quarter of AS patients reported severe side effects from their treatment, most commonly abdominal pain, headache and dizziness, and nausea. There was no effect on age or duration of disease on the occurrence of NSAID-related side effects. Medications were commonly ceased or changed due to inefficacy or side effects. The percentage of AS patients reporting changing their NSAID due to side effects ranged from 10.5% for celecoxib to 31.4% for indomethacin. We conclude that NSAIDs are effective in the management of inflammatory symptoms of many, but not all, patients with AS. There is a significant side effect profile, which frequently results in medication change or cessation. Anti-tumor necrosis factor therapy may reduce the need for intensive long-term NSAID therapy in AS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.